The relatively new drug for Hepatitis C, Sovaldi, has caused a rather large controversy about the appropriate price for medication. This NY Times article is one example of the controversy, citing the cost at $1,000 a pill, and $84,000 for a complete treatment.

I'm not asking about what price is appropriate, this is a much more complicated debate and entirely off-topic here. But I am interested in putting the price in context, and the official statement from Gilead paints a rather different picture than most of the articles in the press I read. They state in their policy position:

Sovaldi was priced such that the total regimen cost is comparable to the previous standard of care regimen for genotype 1 patients with hepatitis C.

Is that statement accurate? Is the cost for a complete treatment with Sovaldi comparable to the cost of the existing treatments for Hepatitis C?

1 Answer 1


According to the Dartmouth Medical School:

With the cost per liver transplantation in the range of $280,000 for one year, liver transplantation for hepatitis C alone reaches a cost of nearly $300 million per year.

Moreover, the average lifetime cost for hepatitis C, in the absence of liver transplant, has been estimated to be about $100,000 for individual patients.

According to the NIH (which does not mention liver transplants specifically):

The lifetime cost of an individual infected with HCV in 2011 was estimated at $64,490. However, this cost is significantly higher among individuals with a longer life expectancy.

The big difference seems to be that Sovaldi is a cure and has the entire cost occur within a treatment period of 12 or 24 weeks, whereas existing treatments consisted of "managing" the disease and spread out the cost over years or decades.

You must log in to answer this question.

Not the answer you're looking for? Browse other questions tagged .